 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «123 |
- GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
Trial primary completion date: Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects (clinicaltrials.gov) - Sep 8, 2016
P1, N=30, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Trial primary completion date: Jun 2016 --> Dec 2016
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Trial primary completion date: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 8, 2016
P1, N=27, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Aug 2016 --> Jun 2017
- | GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
New P1 trial: Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer (clinicaltrials.gov) - Apr 1, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
- | GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
Trial completion, Metastases: Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors (clinicaltrials.gov) - Feb 24, 2016
P1, N=31, Completed, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Trial primary completion date: Aug 2016 --> Jun 2017 Recruiting --> Completed
- | GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
New P1 trial: Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects (clinicaltrials.gov) - Dec 31, 2015
P1, N=30, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
- | suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Nov 24, 2015
P1, N=27, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Enrollment open, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=36, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Enrollment change, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2015
P1, N=36, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting N=22 --> 36
- | suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 26, 2015
P1, N=22, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Trial primary completion date, Metastases: A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 19, 2015
P1, N=31, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
N=22 --> 36 Trial primary completion date: Jul 2014 --> Nov 2015
- GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
Trial primary completion date, Metastases: Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors (clinicaltrials.gov) - Apr 14, 2015
P1, N=30, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Trial primary completion date: Jul 2014 --> Nov 2015 Trial primary completion date: Sep 2014 --> Feb 2015
- GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
New P1 trial, Metastases: Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors (clinicaltrials.gov) - Jun 3, 2014
P1, N=30, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
- | suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial, Metastases: A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 2, 2013
P1, N=31, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.